Drug Repurposing Market Size & Growth Forecast 2027–2036, By Segments (Drug Type, End Use, Disease Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Drug Type Segment Analysis: Conventional Small Molecules (Largest & Fastest-Growing Segment)

Conventional small molecules held the largest market share of 64.75% in 2026, supported by their established role in drug discovery, development, and therapeutic applications, as well as the extensive availability of existing safety, pharmacological, and clinical data that can facilitate repurposing efforts. Their well-characterized mechanisms of action and established manufacturing processes can reduce some of the scientific and development uncertainties associated with identifying alternative therapeutic uses, making these compounds particularly suitable for systematic repurposing programs. The segment also benefits from the broad range of small-molecule therapies already approved or extensively studied across diverse disease categories, creating a substantial pool of candidates that can be evaluated for new indications. In addition, advances in computational drug screening, molecular profiling, artificial intelligence-enabled drug discovery, and real-world evidence analysis are strengthening the ability to identify previously unrecognized therapeutic applications for conventional small molecules. These factors are expected to support continued adoption of conventional small molecules while reinforcing their position as the fastest-growing drug type in the drug repurposing market.

End Use Segment Analysis: Biopharmaceutical & Pharmaceutical Companies (Largest & Fastest-Growing Segment)

Biopharmaceutical & pharmaceutical companies accounted for the largest end-use market share of 59.17% in 2026, reflecting their extensive research infrastructure, drug development expertise, established compound libraries, and access to clinical and regulatory capabilities required to advance repurposed therapies. These companies are increasingly integrating drug repurposing into development strategies because identifying new indications for existing compounds can provide opportunities to extend product lifecycles, diversify therapeutic portfolios, and reduce some of the time and resources associated with conventional discovery pathways. Their ability to integrate clinical trial capabilities with pharmacovigilance data, molecular databases, and advanced analytical platforms also enables more systematic identification and validation of potential repurposing opportunities. Partnerships between pharmaceutical companies, research institutions, biotechnology organizations, and data-driven drug discovery providers are further expanding access to candidate compounds and disease-specific insights. As companies seek more efficient approaches to therapeutic development and portfolio optimization, biopharmaceutical & pharmaceutical companies are positioned to remain both the dominant and fastest-growing end-use segment in the drug repurposing market.

Disease Area Segment Analysis: Oncology (Largest & Fastest-Growing Segment)

Oncology held the largest disease area market share of 38.91% in 2026, driven by the substantial unmet need for new treatment options, the biological complexity of cancer, and the availability of extensive clinical and molecular data that can support the identification of alternative therapeutic applications for existing drugs. Drug repurposing has gained particular relevance in cancer research because compounds developed for other conditions may influence pathways, molecular targets, immune responses, or cellular processes that are also implicated in tumor development and progression. The growing use of precision medicine, genomic profiling, biomarker research, and computational approaches is improving the ability to identify potential connections between established drugs and specific cancer subtypes. At the same time, the need for therapies addressing treatment resistance, rare cancers, and limited treatment options is encouraging researchers and developers to investigate existing compounds from new therapeutic perspectives. Continued expansion of cancer research and increasing emphasis on accelerating access to potentially useful therapies are therefore expected to sustain oncology as both the largest and fastest-growing disease area in the drug repurposing market.